The trial compared oral orforglipron with insulin glargine in 2749 adults with type 2 diabetes at increased cardiovascular risk. 86% had established cardiovascular disease and 38% chronic kidney disease at entry. The outcome counted was cardiovascular death, non-fatal myocardial infarction, non-fatal stroke or admission for unstable angina, with non-inferiority set at a hazard ratio below 1.8.
Why it is interesting: First cardiovascular safety evidence for an oral, non-peptide GLP-1 drug, set against an active comparator.
Cite this item
BibTeX
Free sign-up. A digest of the new papers twice a week, grouped by domain.